SCHEMBL20401792

SCHEMBL20401792

CC1(C)OB(c2ccc(C3CCC(c4ccc([N+](=O)[O-])cc4)N3)cc2)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
LPL P06858 6/20 0.41
LIPG Q9Y5X9 6/20 0.41
POLB P06746 2/20 0.41
ALDH1A1 P00352 1/20 0.41
SLC6A3 Q01959 1/20 0.41
RECQL P46063 1/20 0.40
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CRYZ Q08257 1/20 0.37
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CA12 O43570 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2756313 0.90 LMNA (0.38) LMNALPLLIPGPOLBALDH1A1
SCHEMBL20401812 0.87 LIPG (0.51) LPLLIPGCA1CA2CA9
SCHEMBL56104 0.83 LPL (0.52) LPLLIPGALDH1A1RECQLCA1
SCHEMBL20401809 0.81 LMNA (0.53) LMNAPOLBALDH1A1SLC6A3RECQL
SCHEMBL2756395 0.76 LPL (0.45) LPLLIPGCA1CA2CA9
SCHEMBL17947401 0.75 P4HB (0.51) LPLLIPGMEN1KMT2A
SCHEMBL15481277 0.75 P4HB (0.51) LPLLIPGMEN1KMT2A
SCHEMBL1982611 0.74 POLB (0.46) LMNALPLLIPGPOLBALDH1A1
SCHEMBL28426454 0.74 LMNA (0.54) LMNAPOLBALDH1A1SLC6A3RECQL
SCHEMBL20401793 0.74 LMNA (0.47) LMNAPOLBALDH1A1SLC6A3RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS LMNA 3118/4885LPL 1419/4885LIPG 768/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LMNA 3118/4885LPL 1419/4885LIPG 768/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS LMNA 3118/4885LPL 1419/4885LIPG 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.